Miriam Tenorio

Miriam Tenorio

26 Jun, 2025

“I reached out to Celegence with an urgent project that we could not complete internally. Celegence immediately established a team of experts to strategize next steps. They started project execution nearly overnight and worked seamlessly with our internal team. I would strongly recommend Celegence and their team of experts to anyone facing resource challenges or regulatory hurdles.”

Other Related Articles

Devices Incorporating Tissues or Cells of Animal or Human Origin, or Their Derivatives: Data Expectations Under EU MDR

Blog Medical Devices

Devices Incorporating Tissues or Cells of Animal or Human Origin, or Their Derivatives: Data Expectations Under EU MDR

13 May, 2026

Nitrosamine Control Insights: Clarity and Control in EU Risk Assessment

Blog Pharmaceutical

Nitrosamine Control Insights: Clarity and Control in EU Risk Assessment

07 May, 2026

PMCF Under MDR: When is a Healthcare Professional Survey Approach Justifiable?

Blog Medical Devices

PMCF Under MDR: When is a Healthcare Professional Survey Approach Justifiable?

29 Apr, 2026

Dental Medical Devices: Special Considerations for Clinical Evaluation Under EU MDR

Blog Medical Devices

Dental Medical Devices: Special Considerations for Clinical Evaluation Under EU MDR

22 Apr, 2026

MDR Article 117: What It Means — And How We Help You Get Ahead

Blog Medical Devices

MDR Article 117: What It Means — And How We Help You Get Ahead

16 Apr, 2026

Heavy Metals in Pharmaceuticals: A Critical Quality and Safety Imperative

Blog Pharmaceutical

Heavy Metals in Pharmaceuticals: A Critical Quality and Safety Imperative

10 Apr, 2026

EMA Roadmap Update: PMS Capabilities and the End of the Legacy Era

Blog Pharmaceutical

EMA Roadmap Update: PMS Capabilities and the End of the Legacy Era

01 Apr, 2026

Expanded Access Approval : Balancing Urgency and Oversight in Regulatory Affairs

Blog Pharmaceutical

Expanded Access Approval : Balancing Urgency and Oversight in Regulatory Affairs

26 Mar, 2026

View All